Examining protective efficacy of influenza virus NA-containing virus-like particles (VLP) in mouse model of post-influenza bacterial pneumonia caused by Staphylococcus aureus
Abstract
Currently, pneumonia resulting from post-influenza infection still remains a pressing issue. In particular, virtually no studies regarding a role of immune response against influenza virus neuraminidase in regulating host susceptibility to subsequent bacterial superinfection are now available. Virus-like particles represent one of the new and promising approaches in contemporary virology for developing influenza vaccines and studying influenza virus proteins. Upon that, it is possible to obtain virus-like particles carrying individual influenza virus-derived proteins such as neuraminidase and hemagglutinin. This allows to get closer insight into potential role of individual influenza virus proteins for host immune response as well as assess a risk of developing secondary bacterial pneumonia. In this study we examined an immune response against influenza virus NA protein and its impact in generating resistance to secondary bacterial pneumonia by using neuraminidase-bearing virus-like particles. We used an experimental model of secondary bacterial pneumonia induced by Staphylococcus aureus after influenza infection. Animals were preliminarily vaccinated with virus-like particles carrying neuraminidase, hemagglutinin, or both (a cocktail of virus-like particles). In this model vaccinated animals were infected 21 days later with influenza viruses A/Puerto Rico/8/34 (H1N1) and reassortant strain NIBRG-121xp (A/California/04/2009 (pndm H1N1 2009) X A/Puerto Rico/8/34 ( H1N1)…
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.